Cancer: More targeted use of immunotherapy

June 12, 2018, Swiss National Science Foundation
Credit: CC0 Public Domain

Doctors are increasingly fighting cancer by stimulating patients' immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success.

Immunotherapy changes a patient's to allow it to attack cancer and either destroy them or at least keep them from growing. But the therapy only works for a minority of . Researchers supported by the Swiss National Science Foundation (SNSF) have now discovered how to better predict who will respond to the therapy and who will not.

The key is a protein known as PD-1, which sits on the surface of . Until recently, PD-1 was regarded as their Achilles heel because attach to the protein, thereby protecting themselves from immune system attack. "It's as though the tumour were wearing camouflage," says project lead Alfred Zippelius, deputy head of medical oncology at University Hospital Basel. Immunotherapy blocks the attachment site so the immune cells can "see" the cancer again.

An international research group led by Zippelius has now shown that immune cells with the most PD-1 are best able to detect tumours. In addition, these PD-1-rich cells secrete a signalling compound that attracts additional immune cells to help fight the cancer. "Therefore these patients have a better chance of responding to ," says Daniela Thommen, first author of the study, who is currently at the Netherlands Cancer Institute in Amsterdam on an SNSF mobility fellowship.

Increasing the success rate

At present, still only a fraction of patients respond to immunotherapy. "If we could tell from the outset who the therapy will work for, we could increase the success rate. That would reduce side effects and also lower costs," says Zippelius.

The new findings will enable researchers to develop a practical tool that could ultimately help doctors to decide which patients will benefit from a simple immunotherapy approach and which will require more intensive treatment—for example, a combination of chemotherapy and radiation. For that to happen, researchers must first find a way of distinguishing patients based on the amount of PD-1 in their .

Immunotherapy is becoming increasingly important. "What's revolutionary about it is that some patients may remain cured after years of treatment—even in the case of tumours that have otherwise proved resistant to therapy," says Zippelius. In the meanwhile, University Hospital Basel has set up its own tumour board (a group of doctors with different specialities) for immunotherapy.

Explore further: Reducing cholesterol could enhance T-cell cancer immunotherapy

More information: Daniela S. Thommen et al, A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade, Nature Medicine (2018). DOI: 10.1038/s41591-018-0057-z

Related Stories

Reducing cholesterol could enhance T-cell cancer immunotherapy

May 16, 2018
Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer.

Molecular profiling of melanoma tumours explains differences in survival after T cell therapy

November 28, 2017
The more times metastasised melanoma has mutated and the patient's immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration ...

Technology holds personalised cancer vaccine breakthrough

April 10, 2018
University of Queensland researchers have developed a vaccine delivery technology that enables treatment to be tailored precisely for different cancers.

Cancer cells play hide-and-seek with immune system

June 29, 2016
When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.

Molecular 'magnets' could improve cancer immunotherapy

February 8, 2018
Chemicals that attract specialised immune cells toward tumours could be used to develop better immunotherapies for cancer patients, according to new research published in Cell.

Researchers discover new immunotherapy combination effective at killing cancer cells

August 29, 2017
Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body's immune system detect and attack cancerous cells. Doug ...

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.